International Medical Center of Biomaterials Processing and Cryostorage (MOEX:GEMA)
Russia
· Delayed Price · Currency is RUB 672.00
-1.50 (-0.22%)
At close: Jul 8, 2022
MOEX:GEMA Income Statement
Financials in millions RUB. Fiscal year is January - December.
Millions RUB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 367.7 | 348.6 | 283.51 | 254.68 | 265.89 | 242.63 | Upgrade
|
| Revenue Growth (YoY) | 18.95% | 22.96% | 11.32% | -4.22% | 9.59% | 1.69% | Upgrade
|
| Cost of Revenue | 67.62 | 58.72 | 47.95 | 51.67 | 61.82 | 30.87 | Upgrade
|
| Gross Profit | 300.08 | 289.89 | 235.56 | 203 | 204.07 | 211.76 | Upgrade
|
| Selling, General & Admin | 118.77 | 111.74 | 86.2 | 64.41 | 65.52 | 53.69 | Upgrade
|
| Amortization of Goodwill & Intangibles | - | - | - | - | - | 2.1 | Upgrade
|
| Other Operating Expenses | - | - | - | - | - | 5.81 | Upgrade
|
| Operating Expenses | 118.77 | 111.74 | 86.2 | 64.41 | 66.17 | 69.9 | Upgrade
|
| Operating Income | 181.31 | 178.15 | 149.36 | 138.6 | 137.9 | 141.86 | Upgrade
|
| Interest Expense | -34.77 | -34.57 | -33.56 | -17.62 | -3.52 | -6.84 | Upgrade
|
| Interest & Investment Income | 29.05 | 23.85 | 11.98 | 10.54 | 17.48 | 2.24 | Upgrade
|
| Earnings From Equity Investments | - | 9 | 6.53 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.03 | - | - | - | - | -0.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -21.65 | -21.93 | -8.73 | -32 | -18.7 | -14.39 | Upgrade
|
| EBT Excluding Unusual Items | 153.91 | 154.51 | 125.58 | 99.52 | 133.17 | 122.77 | Upgrade
|
| Gain (Loss) on Sale of Assets | -3.29 | -3.29 | 0.2 | -1.35 | -4 | - | Upgrade
|
| Pretax Income | 151.14 | 151.22 | 125.78 | 98.17 | 129.17 | 122.77 | Upgrade
|
| Net Income | 151.14 | 151.22 | 125.78 | 98.17 | 129.17 | 122.77 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | -21.57 | - | Upgrade
|
| Net Income to Common | 151.14 | 151.22 | 125.78 | 98.17 | 150.74 | 122.77 | Upgrade
|
| Net Income Growth | 5.83% | 20.22% | 28.13% | -24.00% | 5.21% | 2.95% | Upgrade
|
| Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Change (YoY) | -0.05% | - | - | -0.00% | 0.00% | 11.11% | Upgrade
|
| EPS (Basic) | 10.13 | 10.13 | 8.42 | 6.58 | 10.10 | 8.22 | Upgrade
|
| EPS (Diluted) | 10.13 | 10.13 | 8.42 | 6.58 | 10.10 | 8.22 | Upgrade
|
| EPS Growth | 5.88% | 20.22% | 28.13% | -34.88% | 22.79% | -7.35% | Upgrade
|
| Free Cash Flow | 246.28 | 237.02 | 209.59 | 231.83 | 239.82 | 132.26 | Upgrade
|
| Free Cash Flow Per Share | 16.50 | 15.88 | 14.04 | 15.53 | 16.06 | 8.86 | Upgrade
|
| Dividend Per Share | 7.700 | 7.700 | 6.420 | 8.022 | 8.650 | - | Upgrade
|
| Dividend Growth | 246.85% | 19.94% | -19.97% | -7.26% | - | - | Upgrade
|
| Gross Margin | 81.61% | 83.16% | 83.09% | 79.71% | 76.75% | 87.28% | Upgrade
|
| Operating Margin | 49.31% | 51.10% | 52.68% | 54.42% | 51.86% | 58.47% | Upgrade
|
| Profit Margin | 41.10% | 43.38% | 44.37% | 38.55% | 56.69% | 50.60% | Upgrade
|
| Free Cash Flow Margin | 66.98% | 67.99% | 73.93% | 91.03% | 90.20% | 54.51% | Upgrade
|
| EBITDA | 190.81 | 187.01 | 157.64 | 142.41 | 142.04 | 148.31 | Upgrade
|
| EBITDA Margin | 51.89% | 53.64% | 55.60% | 55.92% | 53.42% | 61.13% | Upgrade
|
| D&A For EBITDA | 9.5 | 8.86 | 8.28 | 3.81 | 4.14 | 6.45 | Upgrade
|
| EBIT | 181.31 | 178.15 | 149.36 | 138.6 | 137.9 | 141.86 | Upgrade
|
| EBIT Margin | 49.31% | 51.10% | 52.68% | 54.42% | 51.86% | 58.47% | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 242.63 | Upgrade
|
| Advertising Expenses | - | 28.32 | 23.97 | 17.11 | 15.86 | 8.17 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.